Cytoprotective Effects of Mesenchymal Stem Cells During Liver Transplantation From Donors After Cardiac Death in Swine.
Sasajima H., Miyagi S., Yamada S., Kakizaki Y., Kamei T., Unno M.
Animal Study with a reported sample of 5 on Cardiovascular Disease, published in Transplant Proc (2020) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Transplant Proc (2020)
- Country
- United States
- Reported sample size
- 5
- Source database
- PubMed
- PMID
- 32389486
- DOI
- 10.1016/j.transproceed.2020.01.165
- Citations
- 3
Abstract (original English)
Background Liver transplantation from donors after cardiac death (DCDs) can increase the pool of available organs. Recently, mesenchymal stem cells (MSCs) have been used to treat various diseases. Some studies have reported that MSCs improve the outcome of liver transplantation from DCDs in mice. The aim of this study was to evaluate the cytoprotective effects and safety of MSC transplantation on liver grafts from DCDs in swine. Methods For the MSCs, we used swine adipose-derived stem cells (ADSCs). Landrace swine were divided into 3 groups (n = 5) as follows: 1. the heart-beating (HB) group, from which liver grafts were retrieved and transplanted; 2. the DCD group, from which liver grafts were retrieved 10 minutes after apnea-induced cardiac arrest and transplanted; and 3. the ADSC group, from which liver grafts were retrieved as with the DCD group, transplanted, and then infused with 1.0 × 10 7 ADSCs 2 hours after reperfusion. Results In the HB group, all 5 recipients survived for >7 days, whereas all 5 recipients in the DCD group died within 24 hours after transplantation. In the ADSC group, 3 recipients survived for >7 days, whereas 2 recipients died within 4 days after transplantation. The survival rate was significantly higher in the ADSC group than in the DCD group. Conclusions MSCs could protect the function of liver grafts from warm ischemia-reperfusion injury and impr
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Factor XII-A New Therapeutic Target? A Systematic Review
Systematic Review on Cardiovascular Disease, Neuroinflammation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci1 citations - Level AMeta-analysisEurope PMC
Can cell-based therapies bridge the gap between research and reality in the treatment of myocarditis? A systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Regen Ther (2026) — summary generated from the PubMed abstract.
- 2026
Regen Ther - Level AMeta-analysisEurope PMC
Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials
Meta-analysis with a reported sample of 3345 on Cardiovascular Disease, Stroke Research, published in Syst Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 3345
Syst Rev - Level AMeta-analysisEurope PMC
Orally derived mesenchymal stem cells in the treatment of vascular diseases: a systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Sci Rep (2026) — summary generated from the PubMed abstract.
- 2026
Sci Rep - Level ASystematic ReviewEurope PMC
From Preservation to Repair: A Systematic Review of Therapeutic Organ Rehabilitation During Normothermic Ex Vivo Machine Perfusion
Systematic Review with a reported sample of 12 on Cardiovascular Disease, Immune Modulation, published in Transplant Direct (2026) — summary generated from the PubMed abstract.
- 2026
- n = 12
Transplant Direct - Level AMeta-analysisEurope PMC
Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Meta-analysis on Cardiovascular Disease, Stroke Research, published in Curr Cardiol Rev (2025) — summary generated from the PubMed abstract.
- 2025
Curr Cardiol Rev